The stock has a 36-month beta value of 0.88. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 5 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for BCYC is 65.57M, and at present, short sellers hold a 4.98% of that float. On November 21, 2024, the average trading volume of BCYC was 434.11K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BCYC) stock’s latest price update
The stock of Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) has decreased by -1.72 when compared to last closing price of 20.36. Despite this, the company has experienced a -11.38% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-07 that Today, we revisit Bicycle Therapeutics plc, a clinical-stage biopharma firm, that has intriguing potential and focuses on developing medicines for unmet needs. The company is advancing several candidates within its pipeline and is well-funded into mid-2027. The stock also continues to enjoy strong analyst firm support. An updated analysis of Bicycle Therapeutics follows in the paragraphs below.
BCYC’s Market Performance
BCYC’s stock has fallen by -11.38% in the past week, with a monthly drop of -20.97% and a quarterly drop of -10.59%. The volatility ratio for the week is 5.58% while the volatility levels for the last 30 days are 5.38% for Bicycle Therapeutics Plc ADR The simple moving average for the past 20 days is -13.20% for BCYC’s stock, with a -13.85% simple moving average for the past 200 days.
Analysts’ Opinion of BCYC
Many brokerage firms have already submitted their reports for BCYC stocks, with Stephens repeating the rating for BCYC by listing it as a “Equal-Weight.” The predicted price for BCYC in the upcoming period, according to Stephens is $25 based on the research report published on November 08, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see BCYC reach a price target of $35. The rating they have provided for BCYC stocks is “Outperform” according to the report published on September 06th, 2024.
B. Riley Securities gave a rating of “Neutral” to BCYC, setting the target price at $28 in the report published on August 07th of the current year.
BCYC Trading at -16.93% from the 50-Day Moving Average
After a stumble in the market that brought BCYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.21% of loss for the given period.
Volatility was left at 5.38%, however, over the last 30 days, the volatility rate increased by 5.58%, as shares sank -19.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.71% lower at present.
During the last 5 trading sessions, BCYC fell by -11.58%, which changed the moving average for the period of 200-days by +19.19% in comparison to the 20-day moving average, which settled at $23.05. In addition, Bicycle Therapeutics Plc ADR saw 10.67% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCYC starting from Thompson Travis Alvin, who sale 6,256 shares at the price of $25.11 back on Nov 11 ’24. After this action, Thompson Travis Alvin now owns 19,241 shares of Bicycle Therapeutics Plc ADR, valued at $157,114 using the latest closing price.
Thompson Travis Alvin, the Officer of Bicycle Therapeutics Plc ADR, proposed sale 6,256 shares at $25.11 during a trade that took place back on Nov 11 ’24, which means that Thompson Travis Alvin is holding shares at $157,112 based on the most recent closing price.
Stock Fundamentals for BCYC
Current profitability levels for the company are sitting at:
- -5.95 for the present operating margin
- 0.81 for the gross margin
The net margin for Bicycle Therapeutics Plc ADR stands at -4.51. The total capital return value is set at -0.23. Equity return is now at value -26.82, with -20.45 for asset returns.
Currently, EBITDA for the company is -183.4 million with net debt to EBITDA at 4.85. When we switch over and look at the enterprise to sales, we see a ratio of 13.72. The receivables turnover for the company is 0.64for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.13.
Conclusion
To sum up, Bicycle Therapeutics Plc ADR (BCYC) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
